Role of the Nasal Environment in Obesity

NCT ID: NCT06153654

Last Updated: 2023-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-30

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this study is to investigate the nasal environment in obese and lean individuals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adiposity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Adiposity Olfactory Function Microbiome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese

Obese participants with BMI \>30

No interventions assigned to this group

Lean

Lean participants with a BMI \<25

No interventions assigned to this group

Bariatric

Participants with scheduled bariatric surgery.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

N=50 adult male and female patients with obesity will be included in this study.



* Age 18-55 years
* Written informed consent
* BMI \> 30 kg/m2

N=50 adult lean patients age- and sex-matched to the group of obese patients will be included in this study.


* Age 18-55 years
* Written informed consent
* BMI 18-25 kg/m2

N=50 adult male and female patients with obesity with scheduled bariatric will be included in this study


* Age 18-55 years
* Written informed consent
* BMI \> 35 kg/m2

Exclusion Criteria

* Smoking
* Chronic or acute sinusitis
* Surgical intervention of the nasal cavity or the paranasal sinus
* Use of antibiotics within the last 31 days18
* Current illicit drug abuse including daily marijuana or CBD consumption (≤ 24 g of alcohol per day allowed)
* Any kind of severe chronic disease (e.g. severe heart failure, active cancer disease)
* Use of any kind of decongestant more than twice a week
* Use of cortisone-containing nasal spray within the last 3 months
* Acute allergic rhinitis
* History of neurodegenerative diseases
* History of severe head trauma
* Severe renal impairment (e.g. estimated glomerular filtration rate \<30 ml/min/m2)
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Katharina Timper

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Katharina Timper

Prof. Dr. med.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katharina Timper, Prof. Dr. med.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Basel

Basel, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Katharina Timper, Prof. Dr. med.

Role: CONTACT

Phone: +41 61 328 57 42

Email: [email protected]

Anouk Hoogkamer

Role: CONTACT

Phone: +41 61 328 55 20

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Katharina Timper, Prof.Dr.med.

Role: primary

Anouk Hoogkamer

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-01090

Identifier Type: -

Identifier Source: org_study_id